Design of phase II cancer trials using a continuous endpoint of change in tumor size : Application to a study of sorafenib and erlotinib in non-small-cell lung cancer
- Author
- KARRISON, Theodore G1 2 ; MAITLAND, Michael L2 3 4 ; STADLER, Walter M2 3 ; RATAIN, Mark J2 3 4
[1] Department of Health Studies, University of Chicago, Chicago, IL, United States
[2] Cancer Research Center, University of Chicago, Chicago, IL, United States
[3] Department of Medicine, University of Chicago, Chicago, IL, United States
[4] Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, IL, United States - Source
Journal of the National Cancer Institute. 2007, Vol 99, Num 19, pp 1455-1461, 7 p ; ref : 37 ref
- ISSN
- 0027-8874
- Scientific domain
- Medical oncology
- Publisher
- Oxford University Press, Cary, NC
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Cancer du poumon Cancérologie Carcinome non petite cellule bronchopulmonaire Chimiothérapie Erlotinib Essai clinique phase II Homme Sorafénib Traitement Volume Inhibiteur de la tyrosine kinase Inhibiteur multikinase Appareil respiratoire pathologie Bronche pathologie Enzyme Inhibiteur enzyme Poumon pathologie Protein-tyrosine kinase Quinazoline dérivé Récepteur facteur croissance épiderme Transferases Tumeur maligne
- Keyword (en)
- Antineoplastic agent Lung cancer Cancerology non-small cell lung carcinoma Chemotherapy Erlotinib Phase II trial Human Sorafenib Treatment Volume Respiratory disease Bronchus disease Enzyme Enzyme inhibitor Lung disease Protein-tyrosine kinase Quinazoline derivatives Epidermal growth factor receptor Transferases Malignant tumor
- Keyword (es)
- Anticanceroso Cáncer del pulmón Cancerología Carcinoma no pequeňa célula bronchopulmonar Quimioterapia Erlotinib Ensayo clínico fase II Hombre Sorafenib Tratamiento Volumen Aparato respiratorio patología Bronquio patología Enzima Inhibidor enzima Pulmón patología Protein-tyrosine kinase Receptor factor crecimiento epidermi Transferases Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R02 Chemotherapy
- Discipline
- Pharmacological treatments Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 19147937
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1093/jnci/djm158 
https://dx.doi.org/10.1093/jnci/djm158
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:19:\"10.1093\/jnci\/djm158\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:166:\"Design of phase II cancer trials using a continuous endpoint of change in tumor size : Application to a study of sorafenib and erlotinib in non-small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:40:\"Journal of the National Cancer Institute\";s:9:\"\u0000*\u0000stitle\";s:20:\"J. Natl. Cancer Inst\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"99\";s:8:\"\u0000*\u0000issue\";s:2:\"19\";s:8:\"\u0000*\u0000spage\";s:4:\"1455\";s:8:\"\u0000*\u0000epage\";s:4:\"1461\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0027-8874\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"KARRISON\";s:10:\"\u0000*\u0000aufirst\";s:10:\"Theodore G\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:19:\"MAITLAND, Michael L\";i:1;s:17:\"STADLER, Walter M\";i:2;s:14:\"RATAIN, Mark J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:166:\"Design of phase II cancer trials using a continuous endpoint of change in tumor size : Application to a study of sorafenib and erlotinib in non-small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:8:\"Cary, NC\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:19:\"10.1093\/jnci\/djm158\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:166:\"Design of phase II cancer trials using a continuous endpoint of change in tumor size : Application to a study of sorafenib and erlotinib in non-small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:40:\"Journal of the National Cancer Institute\";s:9:\"\u0000*\u0000stitle\";s:20:\"J. Natl. Cancer Inst\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"99\";s:8:\"\u0000*\u0000issue\";s:2:\"19\";s:8:\"\u0000*\u0000spage\";s:4:\"1455\";s:8:\"\u0000*\u0000epage\";s:4:\"1461\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0027-8874\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"KARRISON\";s:10:\"\u0000*\u0000aufirst\";s:10:\"Theodore G\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:19:\"MAITLAND, Michael L\";i:1;s:17:\"STADLER, Walter M\";i:2;s:14:\"RATAIN, Mark J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:166:\"Design of phase II cancer trials using a continuous endpoint of change in tumor size : Application to a study of sorafenib and erlotinib in non-small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:8:\"Cary, NC\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:19:\"10.1093\/jnci\/djm158\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:19:\"10.1093\/jnci\/djm158\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:166:\"Design of phase II cancer trials using a continuous endpoint of change in tumor size : Application to a study of sorafenib and erlotinib in non-small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:40:\"Journal of the National Cancer Institute\";s:9:\"\u0000*\u0000stitle\";s:20:\"J. Natl. Cancer Inst\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"99\";s:8:\"\u0000*\u0000issue\";s:2:\"19\";s:8:\"\u0000*\u0000spage\";s:4:\"1455\";s:8:\"\u0000*\u0000epage\";s:4:\"1461\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0027-8874\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"KARRISON\";s:10:\"\u0000*\u0000aufirst\";s:10:\"Theodore G\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:19:\"MAITLAND, Michael L\";i:1;s:17:\"STADLER, Walter M\";i:2;s:14:\"RATAIN, Mark J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:166:\"Design of phase II cancer trials using a continuous endpoint of change in tumor size : Application to a study of sorafenib and erlotinib in non-small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:8:\"Cary, NC\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:19:\"10.1093\/jnci\/djm158\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:166:\"Design of phase II cancer trials using a continuous endpoint of change in tumor size : Application to a study of sorafenib and erlotinib in non-small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:40:\"Journal of the National Cancer Institute\";s:9:\"\u0000*\u0000stitle\";s:20:\"J. Natl. Cancer Inst\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"99\";s:8:\"\u0000*\u0000issue\";s:2:\"19\";s:8:\"\u0000*\u0000spage\";s:4:\"1455\";s:8:\"\u0000*\u0000epage\";s:4:\"1461\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0027-8874\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"KARRISON\";s:10:\"\u0000*\u0000aufirst\";s:10:\"Theodore G\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:19:\"MAITLAND, Michael L\";i:1;s:17:\"STADLER, Walter M\";i:2;s:14:\"RATAIN, Mark J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:166:\"Design of phase II cancer trials using a continuous endpoint of change in tumor size : Application to a study of sorafenib and erlotinib in non-small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:8:\"Cary, NC\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:19:\"10.1093\/jnci\/djm158\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:166:\"Design of phase II cancer trials using a continuous endpoint of change in tumor size : Application to a study of sorafenib and erlotinib in non-small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:40:\"Journal of the National Cancer Institute\";s:9:\"\u0000*\u0000stitle\";s:20:\"J. Natl. Cancer Inst\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"99\";s:8:\"\u0000*\u0000issue\";s:2:\"19\";s:8:\"\u0000*\u0000spage\";s:4:\"1455\";s:8:\"\u0000*\u0000epage\";s:4:\"1461\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0027-8874\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"KARRISON\";s:10:\"\u0000*\u0000aufirst\";s:10:\"Theodore G\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:19:\"MAITLAND, Michael L\";i:1;s:17:\"STADLER, Walter M\";i:2;s:14:\"RATAIN, Mark J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:166:\"Design of phase II cancer trials using a continuous endpoint of change in tumor size : Application to a study of sorafenib and erlotinib in non-small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:8:\"Cary, NC\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
